3 Ways Companies Can Make Healthcare More Affordable
As healthcare costs continue to rise, three data-driven strategies can help companies reduce the expense of employee health benefits – without sacrificing quality.
Diabetes Eradication? The New Chronic Condition Care Playbook and How GLP-1s Are Changing the Game
GLP-1 medications are transforming how we think about chronic disease management and, more importantly, prevention. Ongoing research has found them to be effective in the prevention or treatment of diabetes, heart attacks and strokes, kidney disease, liver disease, sleep apnea, and more.
presented by
The Best Options for Diagnostic Imaging Covered by Medicare
Health care professionals can refer patients to the best options for diagnostic imaging covered by Medicare to give more people the medical assistance they need without extra financial stress.
Pfizer Stops Work on Oral GLP-1 Obesity Drug After Safety Signal Surfaces in Clinical Trial
Pfizer said a patient dosed with danuglipron developed potential drug-induced liver injury. Pfizer is stopping further work on this program, a move that comes nearly two years after it discontinued development of a different obesity drug due to liver safety signals in a clinical trial.
How Real-World Data Can Support Label Extension And Safer Use Of Novel Therapies
Engaging in data sharing, observational cohort research, and deeper analysis of available data to yield further insights can drive improved results for patients, making label and cohort extension faster and more robust.
Novo Nordisk’s Next-Gen Obesity Drug Disappoints Again With Lower Than Expected Weight Loss
CagriSema, a dual-acting drug in development by Novo Nordisk, met the goal of a Phase 3 test in patients with obesity and type 2 diabetes. But the topline results don’t show an advantage over Eli Lilly’s commercialized obesity medication, Zepbound.
The Role of Medication Delivery in Non-Adherence
For GLP-1 receptor agonists specifically, adherence challenges are a major concern, as these medications require long-term use to achieve meaningful health benefits in chronic conditions like diabetes and obesity.
presented by
The Top-Rated Orthopedic Surgery Centers in the Houston Area and Beyond
Discover Houston's best orthopedic surgery centers and what features — from personalized treatment plans to rehabilitation services — make these top providers stand out in their industry.
Hims & Hers vs. Novo Nordisk: Are Compounded GLP-1s Safe?
Compounded GLP-1s have become more widespread, but are they safe? Some argue that compounding is nothing new, while others believe these drugs are dangerous for patients.
Some of the Biggest Healthcare Stories from 2024 Involved Pharmacy. What’s Next in 2025?
Regulators will have their work cut out for them under a new administration that has expressed an anti-regulatory preference. Republicans next year will control the White House, Senate and House. What will it all mean for pharmacy leaders?
Metsera’s IPO Raises $275M to Show How Its Obesity Drugs Can Top Current GLP-1s
Investors showed appetite for Metsera’s IPO, as shares of the clinical-stage metabolic medicines biotech popped 47% in their Nasdaq debut. Maze Therapeutics and Beta Bionics also priced IPOs; the three companies raised $636 million combined.
Metabolic Meds Startup Verdiva Launches With $411M and a Weekly Oral GLP-1 Drug
Verdiva Bio’s once-a-week oral GLP-1 drug is ready for Phase 2 testing. The drug, made with a proprietary technology that enables oral dosing, was licensed from Sciwind Biosciences.
presented by
How to Optimize Your Phlebotomy Setup for Efficient Patient Care
The layout of your phlebotomy station can significantly impact efficiency. A well-thought-out setup ensures that every tool is within reach, minimizing unnecessary movement and reducing patient wait times.
A New Era in OSA: Bridging the Gap with Novel Treatment Solutions
We must think beyond one-size-fits-all solutions and embrace the diversity of obstructive sleep apnea. This means continuing to innovate, collaborating across sectors, and keeping patients at the center of every decision.
3 Healthcare Trends to Watch in 2025, Per Red Cell Partners
Leaders from Red Cell Partners, an investment and incubation firm that funds and builds healthcare startups, shared key trends they’re keeping their eyes on this year — including increased adoption of AI agents and redefined GLP-1 management frameworks for employers.
Zocdoc CEO Predicts 3 Ways the Healthcare Industry Will Change in 2025
Zocdoc CEO Oliver Kharraz has some predictions about how healthcare will change in 2025 — including the rise of cash-pay services and the potential restructuring of Amazon’s healthcare assets.
The Dangerous Cycle of Anxiety and Diabetes
Effective diabetes management requires a shift from focusing purely on blood sugar levels and weight management medications to embracing the psychological and biological contributors that drive obesity and the disease.
Weight Loss With Amgen Drug in Line With Eli Lilly Med, But Dosing Could Be Differentiator
Amgen’s experimental obesity drug, MariTide, led to an average 20% reduction in weight in a Phase 2 clinical trial. While investors hoped for greater weight loss, some analysts say less burdensome monthly dosing of MariTide could make it competitive against weekly injectable weight drugs Zepbound and Wegovy.